基于表观遗传学调控的中医药防治心肌缺血再灌注损伤的研究进展  

Research progress in epigenetic regulation of myocardial ischemia/ reperfusion injury by traditional Chinese medicine

作　　者：李光[1,2] 邢小燕[1] 张美双[3] 邓雪红[1] 汤世民 赵娜娜[3] 孙桂波[1] 孙晓波[1] 

机构地区：[1]中国医学科学院药用植物研究所,北京100093 [2]中国医学科学院药用植物研究所云南分所,云南景洪666100 [3]长春中医药大学,吉林长春130117

出　　处：《药学学报》2016年第7期1047-1053,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81503289;81303257);药用植物研究所创新团队发展计划资助(IT1301);中医药行业专项(201507004)

摘　　要：表观遗传学是后基因时代的研究热点,应用表观遗传学修饰的研究方法是心血管疾病机制研究的前沿领域,心肌缺血再灌注损伤是心血管疾病研究领域的难点之一,临床中应用的药物受其不良反应的限制未能广泛应用。中药及其有效组分可多靶点参与调控表观遗传修饰以及心肌缺血再灌注损伤发病的多个环节,这是中药治疗的最大优势。本文综述了基于调控表观遗传学修饰的中药防治心肌缺血再灌注损伤的研究现状及应用前景,以期探讨表观遗传调控与中医理论的内在联系,阐明中药防治心肌缺血再灌注损伤的科学内涵,为后期药物开发提供参考。Epigenetic is a hotspot of post-genomic era research, and epigenetic modification is a mechanism in the study of cardiovascular disease. Myocardial ischemia-reperfusion injury（MIRI） is one of the problems in the cardiovascular disease, and many experimental interventions are reported in the protection of the ischemic myocardium in experimental animals. However, with the exception of early reperfusion, none has been translated into clinical practice. There is an advantage of traditional Chinese medicine（TCM） in the regulation of epigenetic modification, and pathogenesis of myocardial ischemia-reperfusion injury. This review article is prepared to cover the research progress in the treatment of myocardial ischemia-reperfusion injury by TCM with a focus on epigenetic regulation. The epigenetic regulation is documented in TCM theory through a systematic review of the protecting drugs in the MIRI development guidelines.

关 键 词：表观遗传学 心肌缺血再灌注损伤 中药 DNA甲基化 组蛋白修饰 MI RNA 

分 类 号：R965[医药卫生—药理学]